Capmatinib (Tabrecta), tepotinib (Tepmetko), (Cabometyx), cabozantinib, glesatinib, and merestinib are MET inhibitors that directly target the MET protein and reduce the growth of tumor cells in NSCLC. Here, MET is linked to neoplasm.